Comparison of the ABCD Score's Accuracy in Predicting Remission of Type 2 Diabetes Mellitus One Year After Sleeve Gastrectomy, One Anastomosis Gastric Bypass, and Sleeve Gastrectomy with Transit Bipartition.
ABCD score
Remission
Transit bipartition
Type 2 diabetes mellitus
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
08
09
2023
accepted:
13
11
2023
revised:
05
11
2023
medline:
21
11
2023
pubmed:
21
11
2023
entrez:
20
11
2023
Statut:
aheadofprint
Résumé
ABCD score is one of the scoring systems that predicts the probability of T2DM remission after bariatric surgery. Its success in determining T2DM remission after sleeve gastrectomy with transit bipartition (TB) has not yet been validated. The aim of this study was to evaluate the predictive value of ABCD score in TB. Of 438 patients with T2DM, 191 underwent sleeve gastrectomy (SG), 136 underwent one anastomosis gastric bypass (OAGB), and 111 underwent TB. Retrospective analysis of ABCD scores, 1-year postoperative remission rates, and the predictive accuracy of ABCD scores for these were conducted. In the SG, OAGB, and TB groups, respectively, median ABCD scores were 7, 6, and 4, while complete remission rates were 95.3%, 84.6%, and 76.6% (p < 0.001). The area under curves (AUCs) for SG, OAGB, and TB were 0.829 (95% CI = 0.768 to 0.879, p < 0.0001), 0.801 (95% CI = 0.724 to 0.865, p < 0.0001), and 0.840 (95% CI = 0.758 to 0.902, p < 0.0001), respectively. There was no statistically significant difference between AUCs. ABCD score predicts the probability of remission at 1-year follow-up in T2DM patients undergoing TB as accurately as in patients receiving SG or OAGB.
Identifiants
pubmed: 37985569
doi: 10.1007/s11695-023-06950-3
pii: 10.1007/s11695-023-06950-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–9. https://doi.org/10.1001/jama.289.1.76 .
doi: 10.1001/jama.289.1.76
pubmed: 12503980
Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev. 2013;14:939–49. https://doi.org/10.1111/obr.12064 .
doi: 10.1111/obr.12064
pubmed: 23957239
Santoro S, Castro LC, Velhote MC, Malzoni CE, Klajner S, Castro LP, Lacombe A, Santo MA. Sleeve gastrectomy with transit bipartition: a potent intervention for metabolic syndrome and obesity. Ann Surg. 2012;256:104–10. https://doi.org/10.1097/SLA.0b013e31825370c0 .
doi: 10.1097/SLA.0b013e31825370c0
pubmed: 22609843
Plaeke P, Beunis A, Ruppert M, De Man JG, De Winter BY, Hubens G. Review, Performance Comparison, and Validation of Models Predicting Type 2 Diabetes Remission After Bariatric Surgery in a Western European Population. Obes Surg. 2021;31:1549–60. https://doi.org/10.1007/s11695-020-05157-0 .
doi: 10.1007/s11695-020-05157-0
pubmed: 33398626
Ohta M, Seki Y, Ohyama T, Bai R, Kim SH, Oshiro T, Jiang T, Sasaki A, Naitoh T, Yamaguchi T, Inamine S, Miyazaki Y, Ahn SM, Heo Y, Liang H, Choi SH, Yang W, Yao Q, Inoue K, Yamamoto H, Lee HJ, Park YS, Ha TK, Ryu SW, Wang C, Park S, Kasama K. Prediction of Long-Term Diabetes Remission After Metabolic Surgery in Obese East Asian Patients: a Comparison Between ABCD and IMS Scores. Obes Surg. 2021;31:1485–95. https://doi.org/10.1007/s11695-020-05151-6 .
doi: 10.1007/s11695-020-05151-6
pubmed: 33411317
Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, Hanipah ZN, Punchai S, Bhatt DL, Kashyap SR, Burguera B, Lacy AM, Vidal J, Schauer PR. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266:650–7. https://doi.org/10.1097/SLA.0000000000002407 .
doi: 10.1097/SLA.0000000000002407
pubmed: 28742680
Sampaio-Neto J, Nassif LS, Branco-Filho AJ, Bolfarini LA, Loro LS, de Souza MP, Bianco T. External validation of the DiaRem score as a remission predictor of diabetes mellitus type 2 in obese patients undergoing Roux-en-Y gastric bypass. Arq Bras Cir Dig. 2015;28(Suppl 1):19–22. https://doi.org/10.1590/S0102-6720201500S100007 .
doi: 10.1590/S0102-6720201500S100007
pubmed: 26537267
pmcid: 4795300
Eskandaros MS, Abbass A, Ebeid EF, Darwish AA. Remission of type II diabetes mellitus 1-year postoperative following one anastomosis gastric bypass in correlation with ABCD, DiaRem, and DRS scores. Obes Surg. 2022;32:450–6. https://doi.org/10.1007/s11695-021-05793-0 .
doi: 10.1007/s11695-021-05793-0
pubmed: 34780027
Lee WJ, Almulaifi A, Tsou JJ, Ser KH, Lee YC, Chen SC. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: predicting the success by ABCD score. Surg Obes Relat Dis. 2015;11:991–6. https://doi.org/10.1016/j.soard.2014.12.027 .
doi: 10.1016/j.soard.2014.12.027
pubmed: 25868836
Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, Ballem N, Kligman M, Kothari S, ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg Springer, New York LLC. 2015;25:587–606. https://doi.org/10.1007/s11695-015-1645-3 .
doi: 10.1007/s11695-015-1645-3
Shen SC, Wang W, Tam KW, Chen HA, Lin YK, Wang SY, Huang MT, Su YH. Validating risk prediction models of diabetes remission after sleeve gastrectomy. Obes Surg. 2019;29:221–9. https://doi.org/10.1007/s11695-018-3510-7 .
doi: 10.1007/s11695-018-3510-7
pubmed: 30251094
Kodama S, Fujihara K, Horikawa C, Harada M, Ishigoro H, Kaneko M, et al. Network meta-analysis of the relative efficacy of bariatric surgeries for diabetes remission. Obes Rev. 2018;19:1621–9. https://doi.org/10.1111/obr.12751 .
doi: 10.1111/obr.12751
pubmed: 30270528
Lee WJ, Chong K, Chen SC, Zachariah J, Ser KH, Lee YC, Chen JC. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26:2418–24. https://doi.org/10.1007/s11695-016-2120-5 .
doi: 10.1007/s11695-016-2120-5
pubmed: 26932813
Ha J, Kwon Y, Kim NH, Park S, Menzo EL, Rosenthal RJ. Discordance in prediction for prognosis of type 2 diabetes after metabolic surgery: comparison of the ABCD, DiaRem, and individualized metabolic surgery models. Ann Surg Treat Res. 2019;97:309–18. https://doi.org/10.4174/astr.2019.97.6.309 .
doi: 10.4174/astr.2019.97.6.309
pubmed: 31824886
pmcid: 6893221
Calisir A, Ece I, Yilmaz H, Alptekin H, Acar F, Yormaz S, Colak B, Sahin M. The mid-term effects of transit bipartition with sleeve gastrectomy on glycemic control, weight loss, and nutritional status in patients with type 2 diabetes mellitus: a retrospective analysis of a 3-year follow-up. Obes Surg. 2021;31:4724–33. https://doi.org/10.1007/s11695-021-05536-1 .
doi: 10.1007/s11695-021-05536-1
pubmed: 34195935
Karaca FC. Effects of sleeve gastrectomy with transit bipartition on glycemic variables, lipid profile, liver enzymes, and nutritional status in type 2 diabetes mellitus patients. Obes Surg. 2020;30:1437–45. https://doi.org/10.1007/s11695-019-04326-0 .
doi: 10.1007/s11695-019-04326-0
pubmed: 31984455
Al M, Taskin HE. Sleeve gastrectomy with transit bipartition in a series of 883 patients with mild obesity: early effectiveness and safety outcomes. Surg Endosc. 2022;36:2631–42. https://doi.org/10.1007/s00464-021-08769-4 .
doi: 10.1007/s00464-021-08769-4
pubmed: 34671822
Ahuja A, Tantia O, Chaudhuri T, Khanna S, Seetharamaiah S, Majumdar K, Goyal G. Predicting remission of diabetes post metabolic surgery: a comparison of ABCD, diarem, and DRS scores. Obes Surg. 2018;28:2025–31. https://doi.org/10.1007/s11695-018-3136-9 .
doi: 10.1007/s11695-018-3136-9
pubmed: 29435812
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599–612. https://doi.org/10.1038/s41575-021-00448-y .
doi: 10.1038/s41575-021-00448-y
pubmed: 33972770
Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582–9. https://doi.org/10.1002/hep.21768 .
doi: 10.1002/hep.21768
pubmed: 17661414
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associ-ated with normal ALT values. Hepatology. 2003;37:1286–92. https://doi.org/10.1053/jhep.2003.50229 .
doi: 10.1053/jhep.2003.50229
pubmed: 12774006
Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005;42:650–6. https://doi.org/10.1002/hep.20818 .
doi: 10.1002/hep.20818
pubmed: 16037946
Zghebi SS, Mamas MA, Ashcroft DM, Rutter MK, VanMarwijk H, Salisbury C, Mallen CD, Chew-Graham CA, Qureshi N, Weng SF, Holt T, Buchan I, Peek N, Giles S, Reeves D, Kontopantelis E. Development and validation of the DIabetes Severity SCOre (DISSCO) in 139 626 individuals with type 2 diabetes: a retrospective cohort study. BMJ Open Diab Res Care. 2020;8:e000962. https://doi.org/10.1136/bmjdrc-2019-000962 .
doi: 10.1136/bmjdrc-2019-000962
pubmed: 32385076
pmcid: 7228474
Shen SC, Lee WJ, Kasama K, Seki Y, Su YH, Wong SK, Huang YM, Wang W. Efficacy of Different Procedures of Metabolic Surgery for Type 2 Diabetes in Asia: a Multinational and Multicenter Exploratory Study. Obes Surg. 2021;31:2153–60. https://doi.org/10.1007/s11695-021-05239-7 .
doi: 10.1007/s11695-021-05239-7
pubmed: 33523416
Park JY. Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery. J Obes Metab Syndr. 2018;27:213–22. https://doi.org/10.7570/jomes.2018.27.4.213 .
doi: 10.7570/jomes.2018.27.4.213
pubmed: 31089566
pmcid: 6513303
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73. https://doi.org/10.1016/S0140-6736(15)00075-6 .
doi: 10.1016/S0140-6736(15)00075-6
pubmed: 26369473